Our Products
Advanced MRI Contrast Agents
At InLighta BioSciences, we are revolutionizing the field of medical imaging with a new generation of contrast agents designed to enhance diagnostic precision. Our ProCA series includes cutting-edge blood pool agents and targeted contrast agents, offering unparalleled sensitivity and safety.
01
ProCA® Series
ProCA®’s are Protein-based Contrast Agents comprised of altered human protein scaffolds with engineered metal-chelating sites.
ProCA®’s can be utilized as blood-pool agents, or combined with targeting moieties for localized delivery via intravenous injection.
ProCA®s are designed to selectively and tightly bind gadolinium. The resulting stability prevents gadolinium from being replaced by physiological metals like calcium, magnesium, and zinc. This is a significant improvement over current clinical contrast agents, and significantly decreases toxicity risks.
While typical MRI contrast agents enhance imaging through either longitudinal or transverse relaxivity, ProCA®s exhibit high relaxivities for both, resulting in a dual imaging methodology that allows for more precise detection of smaller, early stage tissue abnormalities, that could not yet be detected by current contrast agents.
02
Blood Pool Agents
ProCA®32: Allows for imaging liver tumors that measure less than 0.25 millimeters.
More than 40 times more sensitive than today’s commonly used and clinically-approved agents used to detect tumors in the liver.
In addition to contrast specificity within the liver, ProCA®32 provides full-body contrast as a blood pool agent.
ProCA®32 is currently available for non-clinical laboratory use.
03
Targeted Contrast Agents
Targeted Biomarkers:
Collagen: Structural protein provides strength and elasticity to tissues
EGFR: Cell surface receptor regulating cell growth and division
HER2: Cell receptor in cell growth, linked to breast cancer.
PSMA: Overexpressed in prostate cancer, used for imaging and therapy.
Integrin: Cell adhesion receptors, crucial for cell attachment and signaling.
CXCR4: Chemokine receptor, guides cell migration, implicated in diseases..
CXCR12: Chemokine ligand regulating immune responses and migration.
GRPR: Found in gastrointestinal tissues, targeted in cancer imaging and treatment
What It Does
InLighta BioSciences’ contrast agents are engineered to address the limitations of current imaging technologies, delivering groundbreaking performance and benefits:
Precision Imaging
ProCA contrast agents provide unmatched sensitivity, enabling the detection of smaller abnormalities at earlier stages.
Dual Relaxivity
High relaxivities for both longitudinal and transverse imaging offer more comprehensive diagnostic capabilities.
Targeted Delivery
Combines blood-pool functionality with targeted biomarker recognition for unparalleled accuracy in disease detection.
Safety First
Engineered to tightly bind gadolinium, reducing toxicity risks and improving patient safety.
What It Means to Providers and Patients
For Providers
Gain increased diagnostic confidence with superior image clarity and accuracy.
Detect early-stage abnormalities that were previously undetectable, supporting proactive treatment plans.
Leverage targeted imaging to better localize disease, optimizing treatment strategies.
For Patients
Experience safer diagnostic imaging with reduced risk of gadolinium-related side effects.
Benefit from early disease detection, enabling timely treatment and better health outcomes.
Rest assured with a diagnostic tool designed with safety and accuracy as top priorities.
Get in Touch
For additional information on products, services, or investment opportunities, please contact us using the form below.
"*" indicates required fields
Contact Information
InLighta BioSciences L.L.C.
Atlanta, GA 30303
Atlanta, GA 30303
